BioCentury
ARTICLE | Clinical News

Coveram perindopril/amlopidine: Phase III data

December 10, 2012 8:00 AM UTC

Top-line data from the double-blind, U.S. Phase III PATH trial in 837 patients showed that once-daily oral Coveram produced significantly greater reductions in both seated DBP and SBP from baseline to week 6 compared to either perindopril or amlodipine alone. Coveram was well tolerated with mild to moderate edema, cough and headache reported as the most common adverse events. Xoma said the positive PATH data combined with existing clinical data for Coveram will support an NDA submission, but declined to disclose details. ...